Clinically backed neurology and neurogenetics testing

Powered by expertise from our research labs, clinical labs, and clinical practice, Mayo Clinic Laboratories has developed panels customized to address specific autoimmune neurology and neurogenetic phenotypes. For patients with neurologic conditions, this testing can provide live-changing answers.

Connect with us at the American Academy of Neurology Annual Meeting to learn how our evaluations can inform your clinical practice. Schedule a one-on-one session with our representatives to learn about:

• Why our evaluations are at the leading edge of testing.
• Our collaborative approach to test development.
• The impact our testing has had on patient care.

Autoimmune neurology

Our phenotype-specific evaluations deliver a clear picture of the diagnosis, prognosis, and treatment options for patients. We also continuously integrate antibody discoveries, including Ma2, which is linked to underlying cancer in most patients and involves rapid neurological damage. 

Alzheimer’s disease

Our Alzheimer’s disease evaluations use cerebrospinal fluid biomarkers to achieve a high concordance with amyloid PET scans. Our methodology ensures fast results and provides new hope for correctly diagnosing and managing Alzheimer’s disease and other dementias.

Neuromuscular disease

Using next-generation sequencing, our neuromuscular gene panel enables optimal mutation detection and interpretation. Recent updates to our evaluation ensure we offer a more comprehensive phenotype analysis than other tests on the market, with 217 genes analyzed.

Peripheral neuropathy

Our testing is backed by a multidisciplinary team of clinical peripheral neuropathy experts, laboratory scientists, and genetic counselors. Compared to other available neuropathy panels, ours analyzes an additional 60 carefully vetted genes.